Sign In
Buy CSLLY
$16.35
-0.280 (-1.68%)
At Close: Jun 03, 2026
Carlisle Companies Incorporated $CSL Shares Sold by IFP Advisors Inc
06:10am, Sunday, 19'th Oct 2025
IFP Advisors Inc lessened its holdings in shares of Carlisle Companies Incorporated (NYSE: CSL) by 29.8% during the undefined quarter, according to its most recent 13F filing with the SEC. The institu
My Top 5 Biotech Stocks Big Pharma Could Buy Next
01:29pm, Monday, 06'th Oct 2025
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of
UCLOUDLINK's Groundbreaking PetPhone Launches on HKT's CSL Network in Hong Kong
08:29am, Friday, 26'th Sep 2025
HONG KONG , Sept. 26, 2025 /PRNewswire/ -- UCLOUDLINK GROUP INC.
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
07:00am, Friday, 26'th Sep 2025
SAN DIEGO & ST. GALLEN, Switzerland--(BUSINESS WIRE)---- $TVTX #igan--CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) support the recent publication of the updated clinical practice guideline
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
02:30am, Friday, 26'th Sep 2025
FILSPARI® (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function loss ST. GALLEN, Switzerland, and SAN DIEGO , Sept.
CSL Limited (CSLLY) Q4 2025 Earnings Call Transcript
01:37am, Tuesday, 19'th Aug 2025
CSL Limited (OTCQX:CSLLY) Q4 2025 Earnings Conference Call August 18, 2025 8:00 PM ET Company Participants Andy Schmeltz - Executive Vice President of CSL Behring Chris Cooper - Head of Investor Relat
Australian biopharma firm CSL posts 14% rise in annual profit
05:54pm, Monday, 18'th Aug 2025
Australian biopharmaceutical company CSL reported 14% rise in annual earnings on Tuesday, driven by strong performance at its blood plasma business CSL Behring.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
08:31am, Friday, 01'st Aug 2025
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo
President Trump demands drugmakers slash prices within 60 days
06:54am, Friday, 01'st Aug 2025
CNBC's Joe Kernen reports on the latest news.
ALKS or CSLLY: Which Is the Better Value Stock Right Now?
12:41pm, Tuesday, 01'st Jul 2025
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Alkermes (ALKS) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks pre
Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus
01:00am, Thursday, 26'th Jun 2025
Saint-Herblain, France, June 26, 2025 – Valneva SE, (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an exclusive agreement with CSL Seqirus, one of the world's larg
ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacks Once-monthly dosing reduced HAE attacks by a median of more than 99 percent and a l
KMDA vs. CSLLY: Which Stock Should Value Investors Buy Now?
12:46pm, Wednesday, 28'th May 2025
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Kamada (KMDA) or CSL Limited Sponsored ADR (CSLLY). But which of these two stocks presents in
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
04:00am, Friday, 23'rd May 2025
First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure 1-3 NICE's recommendation is based on clinically meani
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy
07:01am, Tuesday, 29'th Apr 2025
SAN DIEGO & ST. GALLEN, Switzerland--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor are pleased to announce that the European Commission has approved the conversio
